Healthcare Cost-Containment and Drug Price Reduction Risks
First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「Future developments in healthcare cost policy could have a material impact on the Group's operating results and financial position.」
The risk that healthcare cost containment measures in the United States and Japan, including drug price reductions and the promotion of generic drugs, could affect operating results has been reaffirmed. - FY2020RestatedAnnual report
「In advanced healthcare markets, including the United States and Japan, various policies to promote advanced medical care are being implemented.」
The risk that healthcare cost containment measures, drug price reductions and the promotion of generic drugs could affect operating results has been reaffirmed. - FY2019RestatedAnnual report
「In advanced healthcare markets, including the United States and Japan, various policies to promote advanced medical care are being implemented.」
The risks associated with healthcare cost containment, including pressure to reduce originator drug prices, promotion of generic drugs and regular drug price reductions, have been reaffirmed. - FY2017First statedAnnual report
「In the United States and Japan, pressure to reduce the prices of originator drugs, measures to promote the use of lower-priced generic drugs, and regular drug price reductions are being implemented.」
The Company discloses that healthcare cost containment measures in the United States and Japan, pressure to reduce originator drug prices, and the promotion of generic drugs could affect operating results and financial position.